KR20230084166A - Ox40 관련 질환을 치료하는 방법 - Google Patents

Ox40 관련 질환을 치료하는 방법 Download PDF

Info

Publication number
KR20230084166A
KR20230084166A KR1020237011786A KR20237011786A KR20230084166A KR 20230084166 A KR20230084166 A KR 20230084166A KR 1020237011786 A KR1020237011786 A KR 1020237011786A KR 20237011786 A KR20237011786 A KR 20237011786A KR 20230084166 A KR20230084166 A KR 20230084166A
Authority
KR
South Korea
Prior art keywords
weeks
antibody
administration
ser
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237011786A
Other languages
English (en)
Korean (ko)
Inventor
미츠오 사토
요시노리 나가타
겐지 오타키
노부유키 이마이
무네타케 시마베
Original Assignee
쿄와 기린 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쿄와 기린 가부시키가이샤 filed Critical 쿄와 기린 가부시키가이샤
Publication of KR20230084166A publication Critical patent/KR20230084166A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237011786A 2020-10-09 2021-10-08 Ox40 관련 질환을 치료하는 방법 Withdrawn KR20230084166A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063089809P 2020-10-09 2020-10-09
US63/089,809 2020-10-09
US202063116365P 2020-11-20 2020-11-20
US63/116,365 2020-11-20
US202163233592P 2021-08-16 2021-08-16
US63/233,592 2021-08-16
PCT/JP2021/037481 WO2022075476A1 (en) 2020-10-09 2021-10-08 Method for treating ox40 related disease

Publications (1)

Publication Number Publication Date
KR20230084166A true KR20230084166A (ko) 2023-06-12

Family

ID=81126528

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237011786A Withdrawn KR20230084166A (ko) 2020-10-09 2021-10-08 Ox40 관련 질환을 치료하는 방법

Country Status (11)

Country Link
US (1) US20230383001A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225371A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545084A (cg-RX-API-DMAC7.html)
KR (1) KR20230084166A (cg-RX-API-DMAC7.html)
CN (1) CN116437955A (cg-RX-API-DMAC7.html)
AU (1) AU2021358274A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198414A1 (cg-RX-API-DMAC7.html)
IL (1) IL301935A (cg-RX-API-DMAC7.html)
MX (1) MX2023004113A (cg-RX-API-DMAC7.html)
TW (1) TW202222343A (cg-RX-API-DMAC7.html)
WO (1) WO2022075476A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
IL326123A (en) * 2023-07-25 2026-03-01 Inmagene Pte Ltd Methods of treating alopecia areata and atopic dermatitis
WO2025244002A1 (ja) * 2024-05-21 2025-11-27 国立大学法人京都大学 ベンダムスチンによるt細胞の減少を抑制するために使用されるt細胞減少抑制剤
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease
WO2026145427A1 (en) * 2024-12-30 2026-07-09 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Bispecific antibodies targeting ox40 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196359A1 (en) 2005-11-25 2010-08-05 Shinichiro Kato Human Monoclonal Antibody Human CD134 (Ox40) and Methods of Making and Using Same
WO2019229155A1 (en) 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
RU2759630C2 (ru) * 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
TWI787203B (zh) * 2016-09-23 2022-12-21 美商建南德克公司 Il-13拮抗劑用於治療異位性皮炎之用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196359A1 (en) 2005-11-25 2010-08-05 Shinichiro Kato Human Monoclonal Antibody Human CD134 (Ox40) and Methods of Making and Using Same
WO2019229155A1 (en) 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NPL 1: Nakagawa et al. J. of Dermatological Science, 99: 82-89, 2020

Also Published As

Publication number Publication date
US20230383001A1 (en) 2023-11-30
CA3198414A1 (en) 2022-04-14
JP2023545084A (ja) 2023-10-26
TW202222343A (zh) 2022-06-16
AU2021358274A1 (en) 2023-05-25
WO2022075476A1 (en) 2022-04-14
EP4225371A4 (en) 2024-11-20
MX2023004113A (es) 2023-06-29
IL301935A (en) 2023-06-01
AU2021358274A9 (en) 2024-05-30
EP4225371A1 (en) 2023-08-16
CN116437955A (zh) 2023-07-14

Similar Documents

Publication Publication Date Title
JP6637113B2 (ja) Il−4rアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
WO2022075476A1 (en) Method for treating ox40 related disease
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
CN114173816A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
JP2022028788A (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
JP2024517796A (ja) 抗baffr抗体を使用するループス腎炎の治療
JP2024518542A (ja) 皮膚筋炎を処置する方法
JP2023504679A (ja) インターロイキン-17(il-17)アンタゴニストを使用して扁平苔癬を治療する方法
JP2017193541A (ja) 関節リウマチを治療するための医薬組成物
WO2025214333A1 (zh) 抗tslp抗体治疗与tslp相关的炎症疾病的方法
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
TW202041536A (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
CN108473576A (zh) 用于治疗复发形式的多发性硬化的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202